
    
      This is a pilot, single-center, open-label, sequential immune apheresis plasma volume
      escalation cohort study of reduction of soluble Tumor Necrosis Factors Receptors 1/2
      (sTNFR1/2), with or without Nivolumab, in patients with inoperable or metastatic solid
      Tumors. This study evaluates Immunicom fs LW-02 device used with Spectra Optia apheresis
      system, aiming to answer two different study questions:

        -  Safety, tolerability and effectiveness of the device.

        -  Safety, tolerability and effectiveness of the device, employed as monotherapy, or
           combined with Nivolumab.
    
  